Something
important
happened
in
Florida
on
July
1st
that
most
healthcare
professionals
probably
missed
—
the
state
quietly
passed
a
law
allowing
physicians
to
offer
patients
certain
stem
cell
treatments
that
have
not
yet
been
approved
by
the
FDA,
for
use
in
treating
specific
indications
and
subject
to
regulatory
compliance.
Across
the
country,
clinicians,
patients,
and
policymakers
are
watching
closely.
Many
see
this
as
a
long-overdue
step
toward
expanding
treatment
options
for
patients
that
are
not
satisfied
with
the
current
standard
of
care.
As
the
demand
for
stem
cell
therapies
continues
to
grow
worldwide,
Florida’s
Senate
Bill
SB‑1768
is
expected
to
bring
about
many
differing
options
across
the
entire
ecosystem.
For
physicians,
it
introduces
an
opportunity
to
offer
patients
new
treatment
alternatives
while
also
putting
a
spotlight
on
the
complex
intersection
of
innovation,
oversight,
and
clinical
ethics,
especially
in
a
space
that
has
long
lacked
regulatory
clarity.
What
the
law
actually
allows
The
law
boils
down
to
this:
licensed
physicians
in
Florida
can
now
use
non-FDA-approved
stem
cell
therapies
within
the
scope
of
practice
for
such
physicians
and
for
therapies
that
are
related
to
orthopedics,
wound
care,
and
pain
management.
Compliance,
however,
is
tightly
regulated.
The
sourcing
requirements
alone
are
quite
stringent.
Physicians
must
make
sure
that
the
biologics
supplier
they
choose
uses
afterbirth
placental
perinatal
stem
cells,
or
human
cells,
tissues,
or
cellular
or
tissue-based
products,
all
obtained
in
an
ethical
manner,
and
that
do
not
involve
stem
cells
derived
from
aborted
fetuses.
In
addition,
the
stem
cells
must
be
retrieved,
manufactured,
and
stored
in
a
facility
that
is
registered
and
regulated
by
the
FDA,
and
accredited
by
the
AABB,
NMDP,
or
AATB.
They
must
follow
current
Good
Manufacturing
Practices
(cGMP)
and
retain
post-thaw
viability
reports
for
each
treatment
lot.
Plus,
any
marketing
materials
must
clearly
state
that
the
therapy
isn’t
FDA
approved.
It
cannot
be
buried
in
fine
print.
Choosing
the
right
supplier
is
essential
for
physicians
to
stay
compliant.
Patient
consent
represents
another
significant
requirement.
The
law
mandates
detailed
informed
consent
documents
that
spell
out
risks,
alternatives,
and
regulatory
status.
The
risks
of
noncompliance
The
consequences
for
cutting
corners
are
steep.
According
to
the
bill’s
official
analysis,
violations
such
as
misrepresenting
treatments,
using
fetal
or
embryo-derived
cells,
or
failing
to
choose
a
biologics
supplier
who
meets
sourcing
standards
could
result
in
felony
charges
and
license
revocation.
While
the
law
is
state-specific,
its
implications
are
national
as
other
states
are
expected
to
follow
Florida’s
initiative.
For
physicians,
this
creates
both
opportunity
and
obligation.
There
is
now
more
room
to
innovate,
but
also
more
pressure
to
ensure
treatments
meet
high
standards
for
safety,
science,
and
transparency.
In
this
environment,
partnering
with
the
right
supplier
is
essential
for
safety.
That
includes
verifying
the
scientific
integrity
of
any
product
used
and
maintaining
clear
documentation
and
consent
protocols.
As
noted
by
New
Regen
Ortho,
some
products
marketed
as
stem
cell
therapies
contain
little
or
no
viable
cells.
Even
with
post-thaw
viability
documentation
in
place,
therapeutic
value
depends
on
how
the
cells
are
sourced,
handled,
and
delivered.
The
burden
of
quality
assurance
will
continue
to
fall
on
providers,
which
is
why
choosing
the
right
supplier
is
essential
to
meet
this
regulatory
standard.
What
this
means
for
the
market
Stem
cell
therapy
has
long
existed
in
a
gray
zone,
caught
between
scientific
promise
and
regulatory
gaps.
Some
providers
operate
with
strong
data
and
clear
protocols,
while
others
rely
on
marketing
that
outpaces
clinical
evidence.
SB‑1768
introduces
structure
where
there
was
once
ambiguity.
By
requiring
more
transparency
around
sourcing,
consent,
and
advertising,
the
law
will
elevate
providers
who
are
already
committed
to
responsible
care.
In
addition,
opportunities
to
expand
the
use
of
stem
cell
therapies
and
obtain
data
surrounding
these
treatments
may
provide
a
faster
and
cheaper
pathway
to
develop
and
improve
these
therapies.
What
physicians
everywhere
should
take
away
You
don’t
have
to
practice
in
Florida
for
this
law
to
matter.
Patient
interest
in
regenerative
care
is
growing
rapidly,
and
physicians
across
the
country
need
to
be
prepared
to
understand
and
consider
advising
patients,
where
applicable,
of
these
stem
cell-related
treatment
options.
As
the
use
of
stem
cells
becomes
more
commonplace,
the
patient
demand
will
increase,
the
science
will
continue
to
improve,
and
the
cost
of
treatment
will
go
down
(it
may
even
be
covered
under
national
health
insurance
plans
in
the
future).
Innovation
requires
accountability
As
other
states
consider
following
Florida’s
lead,
the
responsibility
falls
on
providers
to
push
the
movement
forward.
Access
means
little
without
accountability.
Whether
in
Florida
or
elsewhere,
patients
deserve
therapies
that
are
as
transparent
and
trustworthy.
For
physicians,
the
challenge
is
not
just
navigating
what’s
allowed,
but
making
sure
the
source
of
the
therapeutics
is
from
reliable,
diligent,
and
compliant
suppliers.
Photo:
chombosan,
Getty
Images
Ian
Bothwell
is
currently
the
Chief
Executive
Officer
and
Chief
Financial
Officer
and
a
member
of
the
Board
of
Directors
of
ZEO
ScientifiX,
Inc.,
a
publicly
traded
clinical-stage
biopharmaceutical
company
(OTCQB
“ZEOX”)
focused
on
the
research
and
development
of
biological
therapeutic
platforms
and
is
currently
positioning
itself
to
be
a
leading
provider
of
stem
cell
products
for
physicians
in
Florida
that
comply
with
the
regulations
of
the
new
Florida
legislation
SB
1768.
This
post
appears
through
the MedCity
Influencers
program.
Anyone
can
publish
their
perspective
on
business
and
innovation
in
healthcare
on
MedCity
News
through
MedCity
Influencers. Click
here
to
find
out
how.